Download PDF
Fortschr Neurol Psychiatr 2005; 73(12): 715-727
DOI: 10.1055/s-2004-830256
Originalarbeit
© Georg Thieme Verlag Stuttgart · New York

Fortschritte in Pathogeneseforschung und Therapie der Multiplen Sklerose

Recent Advances in Pathogenesis and Therapy of Multiple SclerosisR.  A.  Linker1, 3 , C.  Stadelmann2 , R.  Diem3 , M.  Bähr1, 3 , W.  Brück1, 2 , R.  Gold1
  • 1Institut für Multiple Sklerose Forschung (Geschäftsführender Vorsitzender: Prof. Dr. med. Ralf Gold), Bereich Humanmedizin, Georg-August-Universität Göttingen und Gemeinnützige Hertie-Stiftung
  • 2Abteilung Neuropathologie (Direktor: Prof. Dr. med. Wolfgang Brück), Bereich Humanmedizin, Georg-August-Universität Göttingen
  • 3Abteilung Neurologie (Direktor: Prof. Dr. med. Mathias Bähr), Bereich Humanmedizin, Georg-August-Universität Göttingen
Further Information

Publication History

Publication Date:
15 December 2005 (online)

    Permissions and Reprints

Zusammenfassung

In dieser Übersichtsarbeit stellen wir die in den letzten Jahren erzielten Fortschritte bei der Erforschung der Multiplen Sklerose dar und diskutieren sie kritisch. Aus klinischen, bildgebenden, pathologischen, immunologischen und tierexperimentellen Studien resultierten neue Erkenntnisse zur Pathogenese und Therapie der MS. Schwerpunkte liegen insbesondere auf neurodegenerativen Aspekten der Erkrankung sowie auf therapierelevanten Befunden, die bereits zu einer deutlichen Verbesserung der Immuntherapie im letzten Jahrzehnt führten. Vor allem bei der schubförmig verlaufenden MS kann seit der Einführung der Immunmodulation mit Interferonen und Glatiramerazetat in vielen Fällen die Krankheit durch adäquate und frühe Behandlung langfristig stabilisiert werden. In naher Zukunft sind neue Immuntherapeutika, aber wahrscheinlich auch individualisierte Behandlungsansätze zu erwarten. Die weitere Entwicklung neurobiologisch-protektiver Strategien soll gezielt das Überleben von Glia- und Nervenzellen fördern.

Abstract

In this article, recent advances in the research on pathogenesis and therapy of multiple sclerosis (MS) will be summarized. New evidence from clinical studies, imaging, histopathology and experimental models are discussed with a focus on neurodegenerative aspects and evidence from recent therapeutic studies. During the last decade, important advances in immunotherapy have been achieved, which proved especially useful for patients with relapsing remitting MS. The introduction of interferons and glatiramer acetate into MS therapy often leads to a stabilization of the disease course if administered adequately and early. The pathogenetic insights presented here may open new avenues for innovative immunodulatory approaches and lead to an individualized MS therapy in the future. Neuroprotective treatment strategies aim at the protection of glial and neuronal cells.

Literatur

  • 1 Ozawa K, Suchanek G, Breitschopf H, Brück W, Budka H, Jellinger K, Lassmann H. Patterns of oligodendroglia pathology in multiple sclerosis.  Brain. 1994;  117 1311-1322
    PubMedGoogle Scholar
  • 2 Lucchinetti C, Brück W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. A quantitative analysis of oligodendrocytes in multiple sclerosis lesions. A study of 113 cases.  Brain. 1999;  122 2279-2295
    CrossrefPubMedGoogle Scholar
  • 3 Lucchinetti C F, Brück W, Rodriguez M, Lassmann H. Distinct patterns of Multiple Sclerosis pathology indicates heterogeneity in pathogenesis.  Brain Pathol. 1996;  6 259-274
    CrossrefPubMedGoogle Scholar
  • 4 Lassmann H, Brück W, Lucchinetti C. Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy.  Trends Mol Med. 2001;  7 115-121
    CrossrefPubMedGoogle Scholar
  • 5 Aboul-Enein F, Rauschka H, Kornek B, Stadelmann C, Stefferl A, Bruck W, Lucchinetti C, Schmidbauer M, Jellinger K, Lassmann H. Preferential loss of myelin-associated glycoprotein reflects hypoxia-like white matter damage in stroke and inflammatory brain diseases.  J Neuropathol Exp Neurol. 2003;  62 (1) 25-33
    PubMedGoogle Scholar
  • 6 Weinshenker B G, O'Brien P C, Petterson T M, Noseworthy J H, Lucchinetti C F, Dodick D W, Pineda A A, Stevens L N, Rodriguez M. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease.  Ann Neurol. 1999;  46 878-886
    CrossrefPubMedGoogle Scholar
  • 7 Yao D-L, Webster H D, Hudson L D, Brenner M, Liu D-S, Escobar A I, Komoly S. Concentric sclerosis (Balo): Morphometric and in situ hybridization study of lesions in six patients.  Ann Neurol. 1994;  35 18-30
    CrossrefPubMedGoogle Scholar
  • 8 Lucchinetti C F, Mandler R N, McGavern D, Brück W, Gleich G, Ransohoff R M, Trebst C, Weinshenker B, Wingerchuk D, Parisi J E, Lassmann H. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica.  Brain. 2002;  125 1450-1461
    CrossrefPubMedGoogle Scholar
  • 9 Bitsch A, Schuchardt J, Bunkowski S, Kuhlmann T, Brück W. Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammation.  Brain. 2000;  123 1174-1183
    CrossrefPubMedGoogle Scholar
  • 10 Kuhlmann T, Lingfeld G, Bitsch A, Schuchardt J, Brück W. Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time.  Brain. 2002;  125 2202-2212
    CrossrefPubMedGoogle Scholar
  • 11 Trapp B D, Peterson J, Ransohoff R M, Rudick R, Mork S, Bo L. Axonal transection in the lesions of multiple sclerosis.  New Engl J Med. 1998;  338 278-285
    CrossrefPubMedGoogle Scholar
  • 12 Davie C A, Barker G J, Webb S, Tofts P S, Thompson A J, Harding A E, McDonald W I, Miller D H. Persistent functional deficit in multiple sclerosis and autosomal dominant cerebellar ataxia is associated with axon loss.  Brain. 1995;  118 1583-1592
    CrossrefPubMedGoogle Scholar
  • 13 Losseff N A, Webb S L, O'Riordan J I, Page R, Wang L, Barker G J, Tofts P S, McDonald W I, Miller D H, Thompson A J. Spinal cord atrophy and disability in multiple sclerosis. A new reproducible and sensitive MRI method with potential to monitor disease progression.  Brain. 1996;  119 701-708
    PubMedGoogle Scholar
  • 14 Peterson J W, Bö L, Mörk S, Chang A, Trapp B D. Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions.  Ann Neurol. 2001;  50 389-400
    CrossrefPubMedGoogle Scholar
  • 15 Bo L, Vedeler C A, Nyland H I, Trapp B D, Mork S J. Subpial demyelination in the cerebral cortex of multiple sclerosis patients.  J Neuropathol Exp Neurol. 2003;  62 (7) 723-732
    PubMedGoogle Scholar
  • 16 Bo L, Vedeler C A, Nyland H, Trapp B D, Mork S J. Intracortical multiple sclerosis lesions are not associated with increased lymphocyte infiltration.  Mult Scler. 2003;  9 (4) 323-331
    CrossrefPubMedGoogle Scholar
  • 17 Bruck W, Kuhlmann T, Stadelmann C. Remyelination in multiple sclerosis.  J Neurol Sci. 2003;  206 (2) 181-185
    CrossrefPubMedGoogle Scholar
  • 18 Bitsch A, Kuhlmann T, Stadelmann C, Lassmann H, Lucchinetti C, Brück W. A longitudinal MRI study of histopathologically defined hypointense multiple sclerosis lesions.  Ann Neurol. 2001;  49 793-796
    CrossrefPubMedGoogle Scholar
  • 19 Reddy H, Narayanan S, Woolrich M, Mitsumori T, Lapierre Y, Arnold D L, Matthews P M. Functional brain reorganization for hand movement in patients with multiple sclerosis: defining distinct effects of injury and disability.  Brain. 2002;  125 (Pt 12) 2646-2657
    CrossrefPubMedGoogle Scholar
  • 20 Kerschensteiner M, Gallmeier E, Behrens L, Leal V V, Misgeld T, Klinkert W EF, Kolbeck R, Hoppe E, Oropeza-Wekerle R-L, Bartke I, Stadelmann C, Lassmann H, Wekerle H, Hohlfeld R. Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation?.  J Exp Med. 1999;  189 865-870
    CrossrefPubMedGoogle Scholar
  • 21 Stadelmann C, Kerschensteiner M, Misgeld T, Brück W, Hohlfeld R, Lassmann H. BDNF and gp145trkB in multiple sclerosis brain lesions: neuroprotective interactions between immune and neuronal cells?.  Brain. 2002;  125 75-85
    CrossrefPubMedGoogle Scholar
  • 22 Steinman L. Multiple sclerosis: a two-stage disease.  Nat Immunol. 2001;  2 (9) 762-764
    CrossrefPubMedGoogle Scholar
  • 23 Ota K, Matsui M, Milford E L, Mackin G A, Weiner H L, Hafler D A. T-cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosis.  Nature. 1990;  346 (6280) 183-187
    CrossrefPubMedGoogle Scholar
  • 24 Pette M, Fujita K, Wilkinson D, Altmann D M, Trowsdale J, Giegerich G, Hinkkanen A, Epplen J T, Kappos L, Wekerle H. Myelin autoreactivity in multiple sclerosis: recognition of myelin basic protein in the context of HLA-DR2 products by T lymphocytes of multiple-sclerosis patients and healthy donors.  Proc Natl Acad Sci USA. 1990;  87 (20) 7968-7972
    PubMedGoogle Scholar
  • 25 Goebels N, Hofstetter H, Schmidt S, Brunner C, Wekerle H, Hohlfeld R. Repertoire dynamics of autoreactive T cells in multiple sclerosis patients and healthy subjects: epitope spreading versus clonal persistence.  Brain. 2000;  123 Pt 3Ž 508-518
    CrossrefPubMedGoogle Scholar
  • 26 Tuohy V K, Yu M, Weinstock-Guttman B, Kinkel R P. Diversity and plasticity of self recognition during the development of multiple sclerosis.  J Clin Invest. 1997;  99 (7) 1682-1690
    PubMedGoogle Scholar
  • 27 Sabatos C A, Chakravarti S, Cha E, Schubart A, Sanchez-Fueyo A, Zheng X X, Coyle A J, Strom T B, Freeman G J, Kuchroo V K. Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance.  Nat Immunol. 2003;  4 (11) 1102-1110
    CrossrefPubMedGoogle Scholar
  • 28 Khademi M, Illes Z, Gielen A W, Marta M, Takazawa N, Baecher-Allan C, Brundin L, Hannerz J, Martin C, Harris R A, Hafler D A, Kuchroo V K, Olsson T, Piehl F, Wallstrom E. T Cell Ig- and mucin-domain-containing molecule-3 (TIM-3) and TIM-1 molecules are differentially expressed on human Th1 and Th2 cells and in cerebrospinal fluid-derived mononuclear cells in multiple sclerosis.  J Immunol. 2004;  172 (11) 7169-7176
    PubMedGoogle Scholar
  • 29 Shevach E M. Regulatory T cells. Introduction.  Semin Immunol. 2004;  16 (2) 69-71
    CrossrefPubMedGoogle Scholar
  • 30 Viglietta V, Baecher-Allan C, Weiner H L, Hafler D A. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis.  J Exp Med. 2004;  199 (7) 971-979
    CrossrefPubMedGoogle Scholar
  • 31 Takahashi K, Miyake S, Kondo T, Terao K, Hatakenaka M, Hashimoto S, Yamamura T. Natural killer type 2 bias in remission of multiple sclerosis.  J Clin Invest. 2001;  107 (5) R23-R29
    PubMedGoogle Scholar
  • 32 Bayas A, Stazoilek M, Kruse N. et al .Altered regulatory function of plasmacytoid dendritic cells in MS. J Neurol 2004 251 Suppl. 3 III/43
    Google Scholar
  • 33 Kivisakk P, Mahad D J, Callahan M K, Sikora K, Trebst C, Tucky B, Wujek J, Ravid R, Staugaitis S M, Lassmann H, Ransohoff R M. Expression of CCR7 in multiple sclerosis: implications for CNS immunity.  Ann Neurol. 2004;  55 (5) 627-638
    CrossrefPubMedGoogle Scholar
  • 34 Babbe H, Roers A, Waisman A, Lassmann H, Goebels N, Hohlfeld R, Friese M, Schroder R, Deckert M, Schmidt S, Ravid R, Rajewsky K. Clonal expansions of CD8(+) T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction.  J Exp Med. 2000;  192 (3) 393-404
    CrossrefPubMedGoogle Scholar
  • 35 Skulina C, Schmidt S, Dornmair K, Babbe H, Roers A, Rajewsky K, Wekerle H, Hohlfeld R, Goebels N. Multiple sclerosis: brain-infiltrating CD8+ T cells persist as clonal expansions in the cerebrospinal fluid and blood.  Proc Natl Acad Sci USA. 2004;  101 (8) 2428-2433
    CrossrefPubMedGoogle Scholar
  • 36 Tejada-Simon M V, Zang Y C, Hong J, Rivera V M, Zhang J Z. Cross-reactivity with myelin basic protein and human herpesvirus-6 in multiple sclerosis.  Ann Neurol. 2003;  53 (2) 189-197
    CrossrefPubMedGoogle Scholar
  • 37 Derfuss T, Gurkov R, Then B F, Goebels N, Hartmann M, Barz C, Wilske B, Autenrieth I, Wick M, Hohlfeld R, Meinl E. Intrathecal antibody production against Chlamydia pneumoniae in multiple sclerosis is part of a polyspecific immune response.  Brain. 2001;  124 (Pt 7) 1325-1335
    CrossrefPubMedGoogle Scholar
  • 38 Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity.  Nat Immunol. 2001;  2 (8) 675-680
    CrossrefPubMedGoogle Scholar
  • 39 Wekerle H, Kojima K, Lannes-Vieira J, Lassmann H, Linington C. Animal models.  Ann Neurol. 1994;  36 47-53
    CrossrefPubMedGoogle Scholar
  • 40 Rivers T M, Sprunt D H, Berry G P. Observations on attempts to produce acute disseminated encephalomyelitis in monkeys.  J Exp Med. 1933;  58 39-53
    CrossrefPubMedGoogle Scholar
  • 41 Cornet A, Liblau R. Experimentelle Autoimmunenzephalomyelitis. 2003: 80-100
    Google Scholar
  • 42 Ben-Nun A, Wekerle H, Cohen I R. The rapid isolation of clonable antigen-specific T lymphocyte lines capable of mediating autoimmune encephalomyelitis.  Eur J Immunol. 1981;  11 195-199
    CrossrefPubMedGoogle Scholar
  • 43 Sundvall M, Jirholt J, Yang H T, Jansson L, Engstrom A, Pettersson U, Holmdahl R. Identification of murine loci associated with susceptibility to chronic experimental autoimmune encephalomyelitis.  Nat Genet. 1995;  10 (3) 313-317
    PubMedGoogle Scholar
  • 44 Kuchroo V K, Umetsu D T, DeKruyff R H, Freeman G J. The TIM gene family: emerging roles in immunity and disease.  Nat Rev Immunol. 2003;  3 (6) 454-462
    CrossrefPubMedGoogle Scholar
  • 45 Storch M K, Stefferl A, Brehm U, Weissert R, Wallström E, Kerschensteiner M, Olsson T, Linington C, Lassmann H. Autoimmunity to myelin oligodendrocyte glycoprotein in rats mimics the spectrum of multiple sclerosis pathology.  Brain Pathol. 1998;  8 681-694
    PubMedGoogle Scholar
  • 46 Flügel A, Berkowicz T, Ritter T, Labeur M, Jenne D E, Li Z, Ellwart J W, Willem M, Lassmann H, Wekerle H. Migratory activity and functional changes of green fluorescent effector cells before and during experimental autoimmune encephalomyelitis.  Immunity. 2001;  14 547-560
    CrossrefPubMedGoogle Scholar
  • 47 t'Hart B A, van Meurs M, Brok H P, Massacesi L, Bauer J, Boon L, Bontrop R E, Laman J D. A new primate model for multiple sclerosis in the common marmoset.  Immunol Today. 2000;  21 (6) 290-297
    CrossrefPubMedGoogle Scholar
  • 48 t'Hart B A, Vervoordeldonk M, Heeney J L, Tak P P. Gene therapy in nonhuman primate models of human autoimmune disease.  Gene Ther. 2003;  10 (10) 890-901
    CrossrefPubMedGoogle Scholar
  • 49 Koh D R, Fung-Leung W P, Ho A, Gray D, Acha-Orbea H, Mak T W. Less mortality but more relapses in experimental allergic encephalomyelitis in CD8-/-mice.  Science. 1992;  256 (5060) 1210-1213
    PubMedGoogle Scholar
  • 50 Meyer R, Weissert R, Diem R, Storch M K, de Graaf K L, Kramer B, Bähr M. Acute neuronal apoptosis in a rat model of multiple sclerosis.  J Neurosci. 2001;  21 6214-6220
    PubMedGoogle Scholar
  • 51 Nitsch R, Pohl E E, Smorodchenko A, Infante-Duarte C, Aktas O, Zipp F. Direct impact of T cells on neurons revealed by two-photon microscopy in living brain tissue.  J Neurosci. 2004;  24 (10) 2458-2464
    CrossrefPubMedGoogle Scholar
  • 52 Kornek B, Storch M K, Bauer J, Djamshidian A, Weissert R, Wallstroem E, Stefferl A, Zimprich F, Olsson T, Linington C, Schmidbauer M, Lassmann H. Distribution of a calcium channel subunit in dystrophic axons in multiple sclerosis and experimental autoimmune encephalomyelitis.  Brain. 2001;  124 1114-1124
    CrossrefPubMedGoogle Scholar
  • 53 Craner M J, Kataoka Y, Lo A C, Black J A, Baker D, Waxman S G. Temporal course of upregulation of Na(v)1.8 in Purkinje neurons parallels the progression of clinical deficit in experimental allergic encephalomyelitis.  J Neuropathol Exp Neurol. 2003;  62 (9) 968-975
    PubMedGoogle Scholar
  • 54 Craner M J, Lo A C, Black J A, Waxman S G. Abnormal sodium channel distribution in optic nerve axons in a model of inflammatory demyelination.  Brain. 2003;  126 (Pt 7) 1552-1561
    CrossrefPubMedGoogle Scholar
  • 55 Linker R A, Mäurer M, Gaupp S, Martini R, Holtmann B, Giess R, Rieckmann P, Lassmann H, Toyka K V, Sendtner M, Gold R. CNTF is a major protective factor in demyelinating CNS disease: a neurotrophic cytokine as modulator in neuroinflammation.  Nature Med. 2002;  8 620-624
    CrossrefPubMedGoogle Scholar
  • 56 Sättler M, Merkler D, Maier K, Stadelmann C, Ehrenreich H, Bähr M, Diem R. Neuroprotective effects and intracellular signaling pathways of erythropoietin in a rat model of multiple sclerosis. Cell Death Differ 2004; Im Druck
    Google Scholar
  • 57 Bechtold D A, Kapoor R, Smith K J. Axonal protection using flecainide in experimental autoimmune encephalomyelitis.  Ann Neurol. 2004;  55 (5) 607-616
    CrossrefPubMedGoogle Scholar
  • 58 MS-Therapie Konsensusgruppe . Immunmodulatorische Stufentherapie der Multiplen Sklerose.  Nervenarzt. 1999;  70 371-386
    CrossrefPubMedGoogle Scholar
  • 59 Grauer O, Offenhausser M, Schmidt J, Toyka K V, Gold R. Glucocorticosteroid therapy in optic neuritis and multiple sclerosis. Evidence from clinical studies and practical recommendations.  Nervenarzt. 2001;  72 (8) 577-589
    CrossrefPubMedGoogle Scholar
  • 60 Krauss S, Brand M D, Buttgereit F. Signaling takes a breath - new quantitative perspectives on bioenergetics and signal transduction.  Immunity. 2001;  15 (4) 497-502
    CrossrefPubMedGoogle Scholar
  • 61 Gold R, Buttgereit F, Toyka K V. Mechanism of action of glucocorticosteroid hormones: possible implications for therapy of neuroimmunological disorders.  J Neuroimmunol. 2001;  117 (1 - 2) 1-8
    CrossrefPubMedGoogle Scholar
  • 62 Schmidt J, Metselaar J M, Wauben M H, Toyka K V, Storm G, Gold R. Drug targeting by long-circulating liposomal glucocorticosteroids increases therapeutic efficacy in a model of multiple sclerosis.  Brain. 2003;  126 (Pt 8) 1895-1904
    CrossrefPubMedGoogle Scholar
  • 63 Morrow S A, Stoian C A, Dmitrovic J, Chan S C, Metz L M. The bioavailability of IV methylprednisolone and oral prednisone in multiple sclerosis.  Neurology. 2004;  63 (6) 1079-1080
    PubMedGoogle Scholar
  • 64 Keegan M, Pineda A A, McClelland R L, Darby C H, Rodriguez M, Weinshenker B G. Plasma exchange for severe attacks of CNS demyelination: predictors of response.  Neurology. 2002;  58 143-146
    CrossrefPubMedGoogle Scholar
  • 65 Ruprecht K, Klinker E, Dintelmann T, Rieckmann P, Gold R. Plasma exchange for severe optic neuritis: treatment of 10 patients.  Neurology. 2004;  63 (6) 1081-1083
    CrossrefPubMedGoogle Scholar
  • 66 Hartung H P, Kieseier B C. Targets for the therapeutic action of interferon-beta in multiple sclerosis.  Ann Neurol. 1996;  40 (6) 825-826
    CrossrefPubMedGoogle Scholar
  • 67 Bayas A, Rieckmann P. Managing the adverse effects of interferon-beta therapy in multiple sclerosis.  Drug Saf. 2000;  22 (2) 149-159
    PubMedGoogle Scholar
  • 68 Filippini G, Munari L, Incorvaia B, Ebers G C, Polman C, D'Amico R, Rice G P. Interferons in relapsing remitting multiple sclerosis: a systematic review.  Lancet. 2003;  361 (9357) 545-552
    CrossrefPubMedGoogle Scholar
  • 69 Brex P A, Ciccarelli O, O'Riordan J I, Sailer M, Thompson A J, Miller D H. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis.  New Engl J Med. 2002;  346 158-164
    CrossrefPubMedGoogle Scholar
  • 70 McDonald W I, Compston A, Edan G, Goodkin D, Hartung H P, Lublin F D, McFarland H F, Paty D W, Polman C H, Reingold S C, Sandberg-Wollheim M, Sibley W, Thompson A, van den Noort S, Weinshenker B Y, Wolinsky J S. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis.  Ann Neurol. 2001;  50 (1) 121-127
    CrossrefPubMedGoogle Scholar
  • 71 Beck R W, Chandler D L, Cole S R, Simon J H, Jacobs L D, Kinkel R P, Selhorst J B, Rose J W, Cooper J A, Rice G, Murray T J, Sandrock A W. Interferon beta-1a for early multiple sclerosis: CHAMPS trial subgroup analyses.  Ann Neurol. 2002;  51 (4) 481-490
    CrossrefPubMedGoogle Scholar
  • 72 PRISMS-4 . Long-term efficacy of interferon-beta-1a in relapsing MS.  Neurology. 2001;  56 (12) 1628-1636
    PubMedGoogle Scholar
  • 73 Durelli L, Verdun E, Barbero P, Bergui M, Versino E, Ghezzi A, Montanari E, Zaffaroni M. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN).  Lancet. 2002;  359 (9316) 1453-1460
    CrossrefPubMedGoogle Scholar
  • 74 Panitch H, Goodin D S, Francis G, Chang P, Coyle P K, O'Connor P, Monaghan E, Li D, Weinshenker B. Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial.  Neurology. 2002;  59 (10) 1496-1506
    CrossrefPubMedGoogle Scholar
  • 75 Sorensen P S, Ross C, Clemmesen K M, Bendtzen K, Frederiksen J L, Jensen K, Kristensen O, Petersen T, Rasmussen S, Ravnborg M, Stenager E, Koch-Henriksen N. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis.  Lancet. 2003;  362 (9391) 1184-1191
    CrossrefPubMedGoogle Scholar
  • 76 Gold R, Heidenreich F, Kappos L. Immunotherapy of multiple sclerosis with glatiramer acetate mechanisms of action and results from therapeutic trials.  Akt Neurol. 2001;  29 345-351
    Article in Thieme ConnectPubMedGoogle Scholar
  • 77 Weber M S, Starck M, Wagenpfeil S, Meinl E, Hohlfeld R, Farina C. Multiple sclerosis: glatiramer acetate inhibits monocyte reactivity in vitro and in vivo.  Brain. 2004;  127 (Pt 6) 1370-1378
    CrossrefPubMedGoogle Scholar
  • 78 Ziemssen T, Kumpfel T, Klinkert W E, Neuhaus O, Hohlfeld R. Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy.  Brain. 2002;  125 2381-2391
    CrossrefPubMedGoogle Scholar
  • 79 Filippi M, Rovaris M, Rocca M A, Sormani M P, Wolinsky J S, Comi G. Glatiramer acetate reduces the proportion of new MS lesions evolving into „black holes”.  Neurology. 2001;  57 731-733
    PubMedGoogle Scholar
  • 80 Comi G, Filippi M, Wolinsky J S. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group.  Ann Neurol. 2001;  49 (3) 290-297
    CrossrefPubMedGoogle Scholar
  • 81 Spina C A. Azathioprine as an immune modulating drug: clinical applications.  Clin Imm All. 1984;  4 415-446
    PubMedGoogle Scholar
  • 82 Tiede I, Fritz G, Strand S, Poppe D, Dvorsky R, Strand D, Lehr H A, Wirtz S, Becker C, Atreya R, Mudter J, Hildner K, Bartsch B, Holtmann M, Blumberg R, Walczak H, Iven H, Galle P R, Ahmadian M R, Neurath M F. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes.  J Clin Invest. 2003;  111 (8) 1133-1145
    CrossrefPubMedGoogle Scholar
  • 83 Kappos L, Patzold U, Dommasch D, Poser S, Haas J, Krauseneck P, Malin J P, Fierz W, Graffenried B U, Gugerli U S. Cyclosporine versus azathioprine in the long-term treatment of multiple sclerosis-results of the German multicenter study.  Ann Neurol. 1988;  23 (1) 56-63
    CrossrefPubMedGoogle Scholar
  • 84 Yudkin P L, Ellison G W, Ghezzi A, Goodkin D E, Hughes R A, McPherson K, Mertin J, Milanese C. Overview of azathioprine treatment in multiple sclerosis.  Lancet. 1991;  338 (8774) 1051-1055
    CrossrefPubMedGoogle Scholar
  • 85 Stangel M, Gold R. Use of IV immunoglobulins in neurology. Evidence-based consensus.  Nervenarzt. 2004;  75 (8) 801-816
    PubMedGoogle Scholar
  • 86 Lewanska M, Siger-Zajdel M, Selmaj K. No difference in efficacy of two different doses of intravenous immunoglobulins in MS: clinical and MRI assessment.  Eur J Neurol. 2002;  9 (6) 565-572
    CrossrefPubMedGoogle Scholar
  • 87 Gonsette R, Demonty L. Mitoxantrone: a new immunosuppressive agent in multiple sclerosis. 1989: 161-164
    Google Scholar
  • 88 Weilbach F X, Chan A, Toyka K V, Gold R. The cardioprotector dexrazoxane augments therapeutic efficacy of mitoxantrone in experimental autoimmune encephalomyelitis.  Clin Exp Immunol. 2004;  135 (1) 49-55
    CrossrefPubMedGoogle Scholar
  • 89 Hartung H P, Gonsette R, Konig N, Kwiecinski H, Guseo A, Morrissey S P, Krapf H, Zwingers T. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial.  Lancet. 2002;  360 (9350) 2018-2025
    CrossrefPubMedGoogle Scholar
  • 90 Strotmann J M, Spindler M, Weilbach F X, Gold R, Ertl G, Voelker W. Myocardial function in patients with multiple sclerosis treated with low-dose mitoxantrone.  Am J Cardiol. 2002;  89 (10) 1222-1225
    CrossrefPubMedGoogle Scholar
  • 91 Ghalie R G, Mauch E, Edan G, Hartung H P, Gonsette R E, Eisenmann S, Le Page E, Butine M D, De Goodkin D E. A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis.  Mult Scler. 2002;  8 (5) 441-445
    CrossrefPubMedGoogle Scholar
  • 92 Smith D R, Balashov K E, Hafler D A, Khoury S J, Weiner H L. Immune deviation following pulse cyclophosphamide/methylprednisolone treatment of multiple sclerosis: increased interleukin-4 production and associated eosinophilia.  Ann Neurol. 1997;  42 313-318
    CrossrefPubMedGoogle Scholar
  • 93 Pette M, Hartung H P, Toyka K V. Cyclophosphamide in therapy of chronic progressive multiple sclerosis. Critical analysis of current studies.  Nervenarzt. 1994;  65 (4) 271-274
    PubMedGoogle Scholar
  • 94 Miller D H, Khan O A, Sheremata W A, Blumhardt L D, Rice G P, Libonati M A, Willmer-Hulme A J, Dalton C M, Miszkiel K A, O'Connor P W. A controlled trial of natalizumab for relapsing multiple sclerosis.  N Engl J Med. 2003;  348 (1) 15-23
    CrossrefPubMedGoogle Scholar
  • 95 Leussink V I, Zettl U K, Jander S, Pepinsky R B, Lobb R R, Stoll G, Toyka K V, Gold R. Blockade of signaling via the very late antigen (VLA-4) and its counterligand vascular cell adhesion molecule-1 (VCAM-1) causes increased T cell apoptosis in experimental autoimmune neuritis.  Acta Neuropathol (Berl). 2002;  103 (2) 131-136
    CrossrefPubMedGoogle Scholar
  • 96 Tubridy N, Behan P O, Capildeo R, Chaudhuri A, Forbes R, Hawkins C P, Hughes R A, Palace J, Sharrack B, Swingler R, Young C, Moseley I F, MacManus D G, Donoghue S, Miller D H. The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group.  Neurology. 1999;  53 (3) 466-472
    CrossrefPubMedGoogle Scholar
  • 97 Bielekova B, Richert N, Howard T, Blevins G, Markovic-Plese S, McCartin J, Wurfel J, Ohayon J, Waldmann T A, McFarland H F, Martin R. Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta.  Proc Natl Acad Sci USA. 2004;  101 (23) 8705-8708
    CrossrefPubMedGoogle Scholar
  • 98 Horuk R, Shurey S, Ng H P, May K, Bauman J G, Islam I, Ghannam A, Buckman B, Wei G P, Xu W, Liang M, Rosser M, Dunning L, Hesselgesser J, Snider R M, Morrissey M M, Perez H D, Green C. CCR1-specific non-peptide antagonist: efficacy in a rabbit allograft rejection model.  Immunol Lett. 2001;  76 (3) 193-201
    CrossrefPubMedGoogle Scholar
  • 99 Elices M J. BX-471 Berlex.  Curr Opin Investig Drugs. 2002;  3 (6) 865-869
    PubMedGoogle Scholar
  • 100 Litjens N H, Rademaker M, Ravensbergen B, Rea D, van der Plas M J, Thio B, Walding A, Van Dissel J T, Nibbering P H. Monomethylfumarate affects polarization of monocyte-derived dendritic cells resulting in down-regulated Th1 lymphocyte responses.  Eur J Immunol. 2004;  34 (2) 565-575
    CrossrefPubMedGoogle Scholar
  • 101 Neuhaus O, Stuve O, Zamvil S S, Hartung H P. Are statins a treatment option for multiple sclerosis?.  Lancet Neurol. 2004;  3 (6) 369-371
    PubMedGoogle Scholar
  • 102 Vollmer T, Key L, Durkalski V, Tyor W, Corboy J, Markovic-Plese S, Preiningerova J, Rizzo M, Singh I. Oral simvastatin treatment in relapsing-remitting multiple sclerosis.  Lancet. 2004;  363 (9421) 1607-1608
    CrossrefPubMedGoogle Scholar
  • 103 Wiendl H, Hohlfeld R. Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials.  BioDrugs. 2002;  16 (3) 183-200
    PubMedGoogle Scholar
  • 104 Heinze T. et al . Symptomatische Therapie der Multiplen Sklerose.  Nervenarzt. 2004;  75 (Suppl. 1) 2-39
    PubMedGoogle Scholar
  • 105 Gold R, Toyka K V. Immuntherapie neurologischer Erkrankungen. Bremen: Uni-Med 2001:
    Google Scholar

Prof. Dr. med. Ralf Gold

Institut für Multiple Sklerose Forschung · Bereich Humanmedizin der Georg-August-Universität und Gemeinnützige Hertie-Stiftung

Waldweg 33

37073 Göttingen

Email: r.gold@med.uni-goettingen.de

      >